UKCA
Class IIa medical device platform
CyberLiver combines AI-driven remote monitoring with a managed clinical service, keeping patients managed safely at home and out of hospital, and configured to each clinical pathway.
Advanced liver disease carries a high human and healthcare cost: frequent emergency visits, repeated hospitalisation, and deterioration that often goes undetected between appointments. Up to half of these hospitalisations are preventable with continuous monitoring and timely intervention.
CyberLiver is a configurable digital medicine platform, not a single app. Its AI engines interpret data streaming from patients at home, prioritise those who need attention, and trigger clinical escalation before a crisis develops. The same platform is configured to each clinical pathway.
Every configuration is delivered as a managed clinical service: technology, devices and registered clinicians working together, so care reaches patients continuously rather than only at the next appointment.
At the core of the platform are validated predictive engines. They learn each patient's own baseline and score deterioration risk continuously, surfacing the people who need clinical attention while there is still time to act.
Because these engines are embedded in regulated medical devices, they carry formal, auditable obligations to stay safe, valid and relevant throughout their lifecycle. Model governance is a regulatory requirement, not an afterthought.
Our clinically validated configurations address the highest-need liver disease pathways, with more in development.
AI-enabled remote management for end-stage liver disease, detecting deterioration early and reducing avoidable readmission. Granted FDA Breakthrough Device designation.
Learn more →A digital therapeutic that helps patients reduce alcohol use and maintain abstinence, with breath-based monitoring and behavioural support. Evaluated in NIHR-funded trials.
Learn more →Personalised monitoring and management for advanced non-alcoholic fatty liver disease, the fastest-growing cause of chronic liver disease. Currently in R&D.
Learn more →Backed by and working with
Whether you're a clinician, commissioner, researcher or investor, we'd like to hear from you.
Get in touch